11th Vaccines Research and Development: All Things Considered
Register by June 8th, 2013 for a 10% discount. Or register 2, and the 3rd goes FREE with the coupon code RCDVB!
Dear Colleague,

GTC is proud to present its 11th Vaccines Research & Development: All Things Considered Conference, to be held in Boston, MA on July 8-10, 2013. As the name indicates, this conference continues a tradition of presenting valuable updates and exposure to all aspects of vaccine development, including research, product design considerations / specifications, manufacturing, regulations, investment, and policy, in a comfortable, interactive and friendly setting. It brings together the leaders in vaccinology from industry, academia, and the government for practical discussions of the future of our discipline.

Development of new vaccines truly requires a consideration of many things. We examine vaccine development from basic research to marketing. We bring together the people who make the discoveries, make the decisions, fund the work and license the vaccines and foster their interaction with the attendees to share their perspectives of the vaccine industry. The latest information on the new malaria, HIV, tumor, and therapeutic vaccines, DNA vaccines, RNA vaccines, adjuvants, mucosal and other delivery mechanisms will be presented, as will updates on governmental priorities, funding and partnership opportunities. Representatives from the HHS, BARDA and NIH as well as NGO will provide a first-hand perspective into current US vaccines policy, regulation and funding as well as updates on the pandemic and bio-defense policy. All aspects from discovery to marketing will be covered.

The 11th Vaccines Research & Development: All Things Considered conference is part of our Infectious Diseases World Summit 2013 and will be held concurrently with two other tracks which are:

2nd Influenza Research & Development
10th Anti-Infectives Partnering and Deal-Making
 
GOLD SPONSOR
Sessions for 2013's agenda are:
  1. Joint Session with 2nd Influenza Research & Development:
         Adjuvants & Delivery Systems
  2. Vaccines for the Developing World
  3. Government & Biodefense Programs
  4. New Vaccines & Future Trends in Vaccine Discovery
  5. DNA & RNA Vaccines
  6. Joint Session with 2nd Influenza Research & Development:
    Developments in a Broadly Reactive / Universal Influenza Vaccine

Members of the Advisory Board:
John Donnelly, Director, Polio Vaccine Development and Scale-up Project, PATH
Nathalie Garcon, Vice President, Head of Global Adjuvant Center for Vaccines, GSK bio
Drew Hannaman, Vice President, Reearch & Development, Ichor Medical Systems
Jon Heinrichs, Director, Microbial Vaccines, Merck
Deborah Fuller, Associate Professor, Microbiology, University of Washington
Joseph Joyce, Director, Vaccines Basic Research, Merck
Janice Moser, Principle Scientist, Sanofi Pasteur
Derek O’Hagan, Global Head of Vaccine Delivery Research, Novartis
Rino Rappuoli, Global Head of Vaccines Research, Novartis
Ken Rosenthal, Professor, Northeastern Ohio Universities College of Medicine
Dan Stinchcomb, Cofounder and CEO, Inviragen
Jerald Sadoff, Chief Medical Officer, Crucell
Jeffrey Ulmer, Global Head, External Research, Novartis
David Weiner, Professor, University of Pennsylvania
Dan Zimmerman, Senior Vice President Research and Development, Cellular Immunology, CEL-SCI Corporation
We look forward to seeing you in Boston!

Best regards,

The 2013 Advisory Committee

Call for Papers!
To be considered for an oral presentation, please submit an abstract here by June 8, 2013. Selected presentations will be based on quality of abstract and availability. Presentation slots fill up fast so please submit your abstract ASAP.

Sponsorship and exhibiting opportunities are available in a range of levels, which can be tailored to fit your needs. Please contact 626-256-6405 x102 or spex@gtcbio.com for more information.

 
Attend ALL GTC Conferences for One Year for only $3995 ($1990 for acad/govt)
Click here to sign up!